GATA2 and acute myeloid leukemia: Conventional intensive chemotherapy in patients with GATA2-related MDR-AML is associated with an increased rate of complications; timely HSCT with intensive myeloablative conditioning, possibly preceded by novel less toxic cytoreductive therapies, should be the preferred approach in these patients.